Myopathy clinical trials at UCSF
2 in progress, 1 open to eligible people
Myopathy is a muscle disease that makes muscles weak. UCSF is testing a new medicine called efgartigimod to see if it helps adults with this condition. The study also checks if the medicine is safe for people to use.
Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
open to eligible people ages 18 years and up
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on https://myositis-study.com/.
San Francisco, California and other locations
Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Active Idiopathic Inflammatory Myopathy
Sorry, accepting new patients by invitation only
The purpose of this study is to measure the long-term safety and tolerability of efgartigimod PH20 SC in adult participants with IIM who previously participated in ARGX-113-2007. Secondary objectives include efficacy measures of efgartigimod PH20 SC in participants with IIM.
San Francisco, California and other locations
Last updated: